High DcR3 expression predicts stage pN2 in gastric cancer

Hepato-Gastroenterology

Volumn 54, Issue 79, 2007, Pages 2172-2176

  Wu, Yulian ^a   Guo, Enqi ^a   Yu, Junxiu ^a   Xie, Qiuping ^a   Chen, Jian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DcR3; Extended D2 lymphadenectomy; Gastric cancer; N staging

Indexed keywords

PROTEIN DCR 3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 37749010885     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boring CC, Squires TS, Tong T, et al: Cancer statistics, 1994. CA Cancer J Clin 1994; 44(1):7-26.
2. Sun XD, Mu R, Zhou YS, et al: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi 2004; 26(1):4-9.
3. Meyer HJ, Jahne J: Lymph node dissection for gastric cancer. Semin Surg Oncol 1999; 17(2):117-124.
4. Roukos DH: Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26(4):243-255.
5. Kodama Y, Sugimachi K, Soejima K, et al: Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981; 5(2):241-248.
6. Maruyama K, Okabayashi K, Kinoshita T: Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11(4):418-425.
7. Roukos DH: Therapeutic value of D2-resection in gastric cancer evaluated with a new concept. UICC Concensus Conference. In: Kim JP, Min JS, Mok YJ (Eds.). Proceedings of the 3rd International Gastric Cancer Congress, Seoul 1999. Bologna (Italy): Monduzzi Editore, 1999; pp. 29-33.
8. Bunt AM, Hermans J, Smit VT, et al: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995; 13(1):19-25.
9. Bonenkamp JJ, Hermans J, Sasako M, et al: Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340(12):908-914.
10. Roukos DH: Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6(1):46-56.
11. Whiting JL, Hallissey MT, Rowlands DC, et al: Redefin ing surgery for gastric cancer. Gastric Cancer 1999; 2(4):226-229.
12. Fukuya T, Honda H, Hayashi T, et al: Lymph node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995; 197(3):705-711.
13. Wakelin SJ, Deans C, Crofts TJ, et al: A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. Eur J Radiol 2002; 41(2):161-167.
14. Dittler HJ, Siewert JR: Role of endoscopic ultrasonography in gastric carcinoma. Endoscopy 1993; 25(2):162-166.
15. Botet JF, Lightdale CJ, Zauber AG, et al: Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 1991; 81(2):426-432.
16. Ziegler K, Sanft C, Zimmer T, et al: Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. Gut 1993; 34(5):604-610.
17. Habermann CR, Weiss F, Riecken R, et al: Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology 2004; 230(2):465-471.
18. Pitti RM, Marsters SA, Lawrence DA, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396(6712):699-703.
19. Wu Y, Han B, Sheng H, et al: Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003; 105(5):724-732.
20. Sobin LH, Wittekind C: International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 5th Edition. New York: Wiley 1997; 59-62.
21. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1(1):10-24.
22. Ko S, Chu KM, Luk JM, et al: Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun 2004; 319(2):562-568.
23. Ishii M, Gama H, Chida N, et al: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95(4):1036-1040.
24. Yu KY, Kwon B, Ni J, et al: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274(20):13733-13736.
25. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16(3):479-492.
26. Mauri DN, Ebner R, Montgomery RI, et al: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8(1):21-30.
27. Takahama Y, Yamada Y, Emoto K, et al: The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002; 5(2):61-68.
28. Bai C, Connolly B, Metzker ML, et al: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 2000; 97(3):1230-1235.
29. Hsu TL, Chang YC, Chen SJ, et al: Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002; 168(10):4846-4853.